RARB and osteosarcoma: Our results suggested that 4 NR modulators, namely, the RARb antagonist LE135, PPARg antagonist T0070907, LXR agonist T0901317 and Rev-Erba agonist SR9011, can significantly suppress osteosarcoma cell growth without exerting toxic effects on normal osteoblast cells.